Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...

Novo Nordisk and Eli Lilly are both raking in billions from their blockbuster weight loss drugs that are also approved to ...

Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

Novo Nordisk (NVO) reportedly plans to phase out production of human insulin pens while it ramps up production of other ...

Researchers at the University of Copenhagen have developed a new weight-loss drug that may surpass the effectiveness of ...

While Novo Nordisk says CagriSema will help users lose up to 25% of weight, duration will be clear when final results of its ...

the chief executive of Ozempic maker Novo Nordisk warned Wednesday. “Honestly, I’m quite alarmed by what we see in the US now ...

Ozempic and related GLP-1 drugs have taken Europe and North America by storm and have quickly become the darling of the ...

Indian drugmakers are preparing for the launch of copycat weight-loss drugs as the world moves towards the patent expiry of ...

A Scandinavian economic behemoth, Novo Nordisk is the highest valued company in Europe at over $500 billion, which exceeds Denmark’s entire GDP. Ironically, Ozempic and Wegovy, as with many of ...

MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access ...